News Releases News Releases HOME HOME

April 8, 2011

Launch of the Osteoporosis Agent “Edirol® Capsule”

Taisho Toyama Pharmaceutical Co., Ltd.[Head Office: Toshima-ku, Tokyo; President: Akira Ohira (hereafter, “Taisho Toyama”)] and Chugai Pharmaceutical Co., Ltd.[Head Office: Chuo-ku, Tokyo; President: Osamu Nagayama (hereafter, “Chugai”)] announced today that eldecalcitol, an active vitamin D3 agent [brand name: Edirol® Capsule 0.5g and 0.75g (hereafter, “Edirol®”)], which obtained approval on January 21, 2011 for the treatment of osteoporosis, has been listed on National Health Insurance drug reimbursement price list on March 11 and will be launched on April 11.

It is estimated that 12 million people have osteoporosis in Japan. It is important to increase bone density and thus reduce the incidence of fractures since osteoporosis-related fractures reduce quality of life, rendering patients bedridden and increase the risk of death. “Edirol®” is an activated vitamin D3 agent which was discovered by Chugai and co-developed with Taisho Pharmaceutical Co., Ltd. [Head Office: Toshima-ku, Tokyo; Chairman and CEO: Akira Uehara]. “Edirol®” marks the first time in 22 years that an active vitamin D3 derivative indicated for the effective treatment of osteoporosis will be offered in Japan as a new drug. “Edirol®,” as a new active vitamin D3 derivative that enhances effect to bone, will contribute to significant improvement of the quality of life of the patients.

Through the provision of the new treatment options, Taisho Toyama and Chugai will continue its effort to contribute to osteoporosis treatment and to make efforts for promoting the proper use.


Product name: Edirol® Capsule 0.5µg
Edirol® Capsule 0.75µg
Generic name: Eldecalcitol
Indication: Osteoporosis
Dosage and administration: Usually, for adults, 0.75µg of eldecalcitol should be orally administered once daily. However, the dosage may be reduced to 0.5µg once daily according to the symptoms.
Date of approval: January 21, 2011
Date of drug price listing: March 11, 2011
Date of launch: April 11, 2011
Shelf life: 2 years 6 months
Drug price: Edirol® Capsule 0.5µg   JPY 68.50 / capsule
Edirol® Capsule 0.75µg   JPY 98.80 / capsule

Edirol® is a registered trademark of Chugai Pharmaceutical Co., Ltd.